Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex
Standard
Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. / Martín, Virginia; Fabelo, Noemí; Santpere, Gabriel; Puig, Berta; Marín, Raquel; Ferrer, Isidre; Díaz, Mario; Puig Martorell, Berta.
in: J ALZHEIMERS DIS, Jahrgang 19, Nr. 2, 01.01.2010, S. 489-502.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex
AU - Martín, Virginia
AU - Fabelo, Noemí
AU - Santpere, Gabriel
AU - Puig, Berta
AU - Marín, Raquel
AU - Ferrer, Isidre
AU - Díaz, Mario
AU - Puig Martorell, Berta
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Lipid rafts are membrane microdomains intimately associated with cell signaling. These biochemical microstructures are characterized by their high contents of sphingolipids, cholesterol and saturated fatty acids and a reduced content of polyunsaturated fatty acids (PUFA). Here, we have purified lipid rafts of human frontal brain cortex from normal and Alzheimer's disease (AD) and characterized their biochemical lipid composition. The results revealed that lipid rafts from AD brains exhibit aberrant lipid profiles compared to healthy brains. In particular, lipid rafts from AD brains displayed abnormally low levels of n-3 long chain polyunsaturated fatty acids (LCPUFA, mainly 22:6n-3, docosahexaenoic acid) and monoenes (mainly 18:1n-9, oleic acid), as well as reduced unsaturation and peroxidability indexes. Also, multiple relationships between phospholipids and fatty acids were altered in AD lipid rafts. Importantly, no changes were observed in the mole percentage of lipid classes and fatty acids in rafts from normal brains throughout the lifespan (24-85 years). These indications point to the existence of homeostatic mechanisms preserving lipid raft status in normal frontal cortex. The disruption of such mechanisms in AD brains leads to a considerable increase in lipid raft order and viscosity, which may explain the alterations in lipid raft signaling observed in AD.
AB - Lipid rafts are membrane microdomains intimately associated with cell signaling. These biochemical microstructures are characterized by their high contents of sphingolipids, cholesterol and saturated fatty acids and a reduced content of polyunsaturated fatty acids (PUFA). Here, we have purified lipid rafts of human frontal brain cortex from normal and Alzheimer's disease (AD) and characterized their biochemical lipid composition. The results revealed that lipid rafts from AD brains exhibit aberrant lipid profiles compared to healthy brains. In particular, lipid rafts from AD brains displayed abnormally low levels of n-3 long chain polyunsaturated fatty acids (LCPUFA, mainly 22:6n-3, docosahexaenoic acid) and monoenes (mainly 18:1n-9, oleic acid), as well as reduced unsaturation and peroxidability indexes. Also, multiple relationships between phospholipids and fatty acids were altered in AD lipid rafts. Importantly, no changes were observed in the mole percentage of lipid classes and fatty acids in rafts from normal brains throughout the lifespan (24-85 years). These indications point to the existence of homeostatic mechanisms preserving lipid raft status in normal frontal cortex. The disruption of such mechanisms in AD brains leads to a considerable increase in lipid raft order and viscosity, which may explain the alterations in lipid raft signaling observed in AD.
KW - Adenosine Triphosphatases
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Alzheimer Disease
KW - Amyloid beta-Protein Precursor
KW - Analysis of Variance
KW - Caveolin 1
KW - Cerebral Cortex
KW - Clathrin
KW - Docosahexaenoic Acids
KW - Female
KW - Humans
KW - Lipids
KW - Male
KW - Membrane Microdomains
KW - Middle Aged
KW - Regression Analysis
KW - Superoxide Dismutase
KW - Young Adult
U2 - 10.3233/JAD-2010-1242
DO - 10.3233/JAD-2010-1242
M3 - SCORING: Journal article
C2 - 20110596
VL - 19
SP - 489
EP - 502
JO - J ALZHEIMERS DIS
JF - J ALZHEIMERS DIS
SN - 1387-2877
IS - 2
ER -